Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease

被引:421
作者
Micha, Renata [1 ]
Imamura, Fumiaki [1 ]
von Ballmoos, Moritz Wyler [2 ,3 ]
Solomon, Daniel H. [4 ,5 ]
Hernan, Miguel A. [1 ,8 ]
Ridker, Paul M. [3 ,6 ,7 ]
Mozaffarian, Dariush [1 ,3 ,6 ,7 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] Childrens Hosp, Dept Cardiac Surg, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Brigham & Womens Hosp, Div Rheumatol, Boston, MA USA
[5] Brigham & Womens Hosp, Div Immunol & Allergy, Boston, MA USA
[6] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[7] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA USA
[8] Harvard MIT Div Hlth Sci & Technol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
LOW-DOSE METHOTREXATE; CORONARY-HEART-DISEASE; RHEUMATOID-ARTHRITIS; MYOCARDIAL-INFARCTION; PREDICTORS; MORTALITY; EVENTS; STROKE; TRIAL; BIAS;
D O I
10.1016/j.amjcard.2011.06.054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammation predicts risk for cardiovascular disease (CVD) events, but the relation of drugs that directly target inflammation with CVD risk is not established. Methotrexate is a disease-modifying antirheumatic drug broadly used for the treatment of chronic inflammatory disorders. A systematic review and meta-analysis of evidence of relations of methotrexate with CVD occurrence were performed. Cohorts, case-control studies, and randomized trials were included if they reported associations between methotrexate and CVD risk. Inclusions and exclusions were independently adjudicated, and all data were extracted in duplicate. Pooled effects were calculated using inverse variance-weighted meta-analysis. Of 694 identified publications, 10 observational studies in which methotrexate was administered in patients with rheumatoid arthritis, psoriasis, or polyarthritis met the inclusion criteria. Methotrexate was associated with a 21% lower risk for total CVD (n = 10 studies, 95% confidence interval [CI] 0.73 to 0.87, p <0.001) and an 18% lower risk for myocardial infarction (n = 5, 95% CI 0.71 to 0.96, p = 0.01), without evidence for statistical between-study heterogeneity (p = 0.30 and p = 0.33, respectively). Among prespecified sources of heterogeneity explored, stronger associations were observed in studies that adjusted for underlying disease severity (relative risk 0.64, 95% CI 0.43 to 0.96, p <0.01) and for other concomitant medication (relative risk 0.73, 95% CI 0.63 to 0.84, p <0.001). Publication bias was potentially evident (funnel plot, Begg's test, p = 0.06); excluding studies with extreme risk estimates did not, however, alter results (relative risk 0.81, 95% CI 0.74 to 0.89). In conclusion, methotrexate use is associated with a lower risk for CVD in patients with chronic inflammation. These findings suggest that a direct treatment of inflammation may reduce CVD risk. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011; 108:1362-1370)
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 30 条
[1]   Risk of Cardiovascular Mortality in Patients With Rheumatoid Arthritis: A Meta-Analysis of Observational Studies [J].
Avina-Zubieta, J. Antonio ;
Choi, Hyon K. ;
Sadatsafavi, Mohsen ;
Etminan, Mahyar ;
Esdaile, John M. ;
Lacaille, Diane .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (12) :1690-1697
[2]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[3]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[4]   Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study [J].
Choi, HK ;
Hernán, MA ;
Seeger, JD ;
Robins, JM ;
Wolfe, F .
LANCET, 2002, 359 (9313) :1173-1177
[5]   Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis [J].
Cronstein, BN .
PHARMACOLOGICAL REVIEWS, 2005, 57 (02) :163-172
[6]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[7]  
EDWARDS CJ, 2008, ARTHRITIS RHEUM S9, V56, P688
[8]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[9]  
Goodson NJ, 2008, RHEUMATOLOGY, V47, pII49
[10]   Safety of low dose methotrexate in elderly patients with rheumatoid arthritis [J].
Hirshberg, B ;
Muszkat, M ;
Schlesinger, O ;
Rubinow, A .
POSTGRADUATE MEDICAL JOURNAL, 2000, 76 (902) :787-789